Abiopharma

AGCO CORP /DE (AGCO) Reports the reporting period Financial Results AGCO CORP /DE (AGCO) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: $1.08
• EPS: $1.08
• Cash and equivalents: $5
  • expected industry conditions, currency fluctuations and a more cautious outlook for the balance of the year, we are adjusting our full-year outlook. Farmers continue to face pressure from elevated operating costs, uneven crop economics and broader macroeconomic uncertainty, resulting in delayed equipment investments and limited visibility into demand recovery. In response, we remain focused on our cost-reduction efforts, closely managing production schedules and prioritizing cash flow and margin performance. While near-term market conditions are difficult, we are confident in the strategic actions we have taken to strengthen AGCO’s competitive position and are committed to executing our Farmer-First strategy, expanding technology adoption and creating long-term value for our shareholders.” Net sales for the first six months of 2026